Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen
Nature Reviews Rheumatology 13, 136 (2017).
doi:10.1038/nrrheum.2017.4
Author: Michael T. Nurmohamed
The PRECISION trial demonstrates that celecoxib is noninferior to ibuprofen and naproxen in regard to cardiovascular safety. Do these findings mark the end of the debate on this issue, or do aspects of the trial mean the implications for clinical practice are not clear-cut?
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Michael T. Nurmohamed Tags: News and Views Source Type: research
More News: Aleve | Cardiology | Cardiovascular | Celebrex | Heart | Ibuprofen | Naproxen | Rheumatology